Washington, D.C.—The Food and Drug Administration (FDA) has created a list of ingredients that FDA believes to be unlawfully marketed in dietary supplements, according to a press release from deputy commissioner for food policy and response Frank Yiannas.
Reasons for an ingredient’s inclusion on the list, according to Yiannas, include the ingredient not fitting the definition of a dietary ingredient, or the ingredient requiring a pre-market notification that was not submitted. That said, Yiannas stressed that inclusion on the list does not necessarily indicate safety concerns, which will be communicated separately. And the list will never stop evolving: New ingredients can be added as they are identified, and others can be removed as concerns are laid to rest.
“As the dietary supplement marketplace has grown,” Yiannas said in the release, “the introduction of new ingredients often raises complex questions involving science, policy, and the law. In the time it takes the FDA to make a final determination, consumers and industry might mistakenly conclude that a lack of action by the FDA indicates that these ingredients are lawful. This List is intended to get information to both consumers and industry more quickly. It also provides an opportunity for stakeholders to share information with us that they think might be relevant to our determination.”
As part of the ongoing effort to keep dietary supplements safe, Yiannas added, FDA is continuing to take action against companies marketing adulterated supplements. FDA issued 11 warning letters to eight companies marketing products containing DMHA and three companies marketing products containing phenibut. DMHA, according to the constituent update regarding the warning letters, is either a new dietary ingredient for which FDA has not received a notification or an unsafe food additive. Phenibut does not meet the definition of a dietary ingredient and can be addictive, with severe side effects and withdrawal symptoms.
The Council for Responsible Nutrition (CRN) released a statement regarding the list. Andrew Shao, Ph.D., interim SVP of scientific & regulatory affairs at CRN, said: “CRN applauds the launch of FDA’s new Dietary Supplement Ingredient Advisory List. Protecting consumers from ingredients that appear to be unlawfully marketed in dietary supplements is a critical component of FDA’s regulatory oversight, and so we are pleased that a new platform to alert consumers more rapidly than in the past has been established. The new tool will allow FDA to exert greater regulatory enforcement in the face of limited resources. CRN stands strong with FDA in its fight against companies who are deliberately violating the law.”
Shao encouraged consumers to bookmark and regularly refer to the list, and encouraged the rest of the dietary supplement industry to embrace it, showing support for FDA’s efforts to preserve the balance between access and safety with regard to dietary supplements.
Shao added: “CRN is eager to collaborate with FDA as the agency unveils initiatives, like the List. In the meantime, we hope the agency’s announcement serves as a clear warning to bad actors in the fringes of our industry—the regulators are coming for you if you attempt to skirt the law.”